With more U.S. biosimilars continuing to receive FDA approval, it is critical that bio/pharmaceutical companies develop strategies to comply with evolving regulations, mitigate risk and execute long-term decisions to prepare for success. CBI’s 13th Biosimilars Summit is the leading event to continually stay on the pulse of the biosimilars’ ever-changing market and convenes key stakeholders including biosimilar and innovator pharmaceutical manufacturers, payers, providers and patient advocates addressing timely challenges and best practices for biosimilar product success.
Who should attend:
You will benefit from attending this event if you are a vice president, director, or manager of a pharmaceutical or biotech company with responsibilities in the following areas:
- Biosimilar Development
- Brand/Marketing
- Sales
- Regulatory Affairs
- Legal
- Intellectual Property
- Business Development
- Portfolio Management
- Corporate Strategy
- Strategic Planning
- Patents
- Policy
- Finance
- Pricing Strategy
- Managed Markets
This conference will also benefit pharmacies, GPOs, health systems, law firms, consultants, discovery firms and software service providers.
Address:
Hilton Alexandria Old Town
1767 King St.
Alexandria, VA
View map